Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-22 are cancelled.

23. (Currently Amended) A method of activating a central nervous system receptor in a subject in need of an effect mediated in the central nervous system, the method comprising ~~bringing said receptor into contact with~~ peripherally administering to the subject an amphiphilic drug-oligomer conjugate comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled with a hydrophilic moiety, and wherein the conjugate traverses the blood-brain barrier of the subject to come into contact with and activate the receptor and thereby produce the effect.

24. (Currently Amended) The method of claim ~~1~~ 23, ~~further characterized in that said~~ wherein the conjugate exhibits activity in the central nervous system ~~the~~ without cleavage of the therapeutic compound from the oligomer.

25. (Currently Amended) The method of claim ~~1~~ 23, wherein the receptor is a G-protein coupled receptor.

26. (Currently Amended) The method of claim ~~1~~ 23, wherein the receptor is an opioid receptor.

27. (Currently Amended) The method of claim ~~1~~ 23, wherein the receptor is an opioid receptor selected from the group consisting of d, μ and ?.

28. (Currently Amended) The method of claim ~~1~~ 23, wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG_{1-7}.

29. (Currently Amended) The method of claim ~~1~~ 23, wherein the hydrophilic moiety is selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.

30. (Currently Amended) The method of claim ~~1~~ 23, wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline and alanine.

31. (Currently Amended) The method of claim ~~1~~ 23, wherein the therapeutic compound is a peptide or protein.

32. (Currently Amended) The method of claim ~~1~~ 23, wherein the therapeutic compound ~~is a peptide and the peptide~~ is selected from the group consisting of: enkephalin, adrenocorticotropic hormone, adenosine deaminase, ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminease, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytocin, papain, parathyroid hormone, prolactin, soluble CD-4, somatomedin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of ~~such peptides~~ any of the foregoing.

33. (Currently Amended) The method of claim ~~1~~ 23, wherein the ~~amphiphilic~~ oligomer is selected from the group of:

$CH_3(CH_2)_n(OC_2H_4)_mOH$ (Formula 1);

wherein n=3 to 25 and m=1 to 6;

$CH_3(CH_2)_n(OC_2H_4)_mOCH_2CO_2H$ (Formula 2);

wherein n=3 to 25 and m=1 to 7;

$CH_3(CH_2)_nCX(OC_2H_4)_mOH$ (Formula 3);

wherein n=3 to 25, m=1 to 7 and X=O or N;

$R\text{-}(OC_2H_4)_mCH_2CO_2H$ (Formula 4);

wherein m=0 to 5 and R=cholesterol or adamantane;

$R\text{-}OCO(C_2H_4O)_mCH_2CO_2H$ (Formula 5);

wherein m=0 to 5;

$CH_3(CH_2—CH=CH)_6(CH_2)_2CH_2(OC_2H_4)_mOH$ (Formula 6);

wherein m=0 to 7; and

$CH_3(CH_2—CH=CH)_6(CH_2)_2C_x(OC_2H_4)_mOH$ (Formula 7);

wherein m=1 to 7 and X=N or O.

34. (Currently Amended) The method of claim ~~1~~ 23, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a ~~hydrolysable~~ hydrolyzable bond.

35. (Currently Amended) The method of claim ~~1~~ 23, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a non-hydrolyzable bond.

Claims 36-63 are cancelled.

64. (Currently Amended) The method of claim ~~1~~ 23, wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

65. (Currently Amended) The method of claim ~~1~~ 23, wherein the therapeutic compound is an enkephalin.

66. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$CH_3(CH_2)_n(OC_2H_4)_mOH$ (Formula 1);

wherein n=3 to 25 and m=1 to 6.

67. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$CH_3(CH_2)_n(OC_2H_4)_mOCH_2CO_2H$ (Formula 2);

wherein n=3 to 25 and m=1 to 7;

68. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$CH_3(CH_2)_nCX(OC_2H_4)_mOH$ (Formula 3);

wherein n=3 to 25, m=1 to 7 and X=O or N;

69. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$R\text{-}(OC_2H_4)_mCH_2CO_2H$ (Formula 4);

wherein m=0 to 5 and R=cholesterol or adamantane;

70. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$R\text{-}OCO(C_2H_4O)_mCH_2CO_2H$ (Formula 5);

wherein m=0 to 5;

71. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$CH_3(CH_2—CH=CH)_6(CH_2)_2CH_2(OC_2H_4)_mOH$ (Formula 6);

wherein m=0 to 7; and

72. (New) The method of claim 23, wherein the conjugate comprises an amphiphilic oligomer having a formula:

$CH_3(CH_2—CH=CH)_6(CH_2)_2C_x(OC_2H_4)_mOH$ (Formula 7);

wherein m=1 to 7 and X=N or O.

73. (New) The method of claim 23, wherein the conjugate is administered to the subject parenterally.

74. (New) The method of claim 23, wherein the conjugate is administered to the subject orally.

75. (New) The method of claim 23, wherein the activation of the receptor induces analgesia in the subject.

76. (New) The method of claim 34, wherein the activation of the receptor induces analgesia in the subject.

77. (New) The method of claim 35, wherein the activation of the receptor induces analgesia in the subject.

78. (New) The method of claim 73, wherein the activation of the receptor induces analgesia in the subject.

79. (New) The method of claim 74, wherein the activation of the receptor induces analgesia in the subject.